Seoul Court Maintains Stance Not To Raise Novartis' Glivec Price; Health Ministry May Appeal To Higher Court
This article was originally published in PharmAsia News
Executive Summary
SEOUL - In what appears to be a victory - at least for now - for multinational pharma companies in their fight against mounting calls for price cuts, a Seoul Administrative Court maintained its earlier stance and ruled that a court-ordered price cut for Novartis' Glivec (imatinib) goes against "fairness" and the purpose of the EU free trade agreement